Publication details
Dose Intensity of Chemotherapy in Patients With Relapsed Hodgkin's Lymphoma.
| Authors | |
|---|---|
| Year of publication | 2010 |
| Type | Article in Periodical |
| Magazine / Source | Journal of clinical oncology |
| MU Faculty or unit | |
| Citation | |
| Field | Oncology and hematology |
| Keywords | Hodgkin lymphoma |
| Description | High-dose chemotherapy (HDCT) followed by autologous stem-cell transplantation (PBSCT) has become the standard treatment for patients (pts) with relapsed Hodgkin's lymphoma (HL). The intensity of treatment needed is unclear. This European intergroup study evaluated the impact of sequential high-dose chemotherapy (SHDCT) before myeloablative therapy. PATIENTS:Pts with histologically confirmed, relapsed HL were treated with two cycles of DHAP. In the standard arm (A), pts received myeloablative therapy with BEAM followed by PBSCT. Pts in the experimental arm (B) also received sequential cyclophosphamide, methotrexate and etoposide in high-doses before BEAM. RESULTS:Mortality was similar in both arms (20% and 18%). With a median observation time of 42 mo., there was no significant difference in terms of FFTF (P = .56) and OS (P = .82) between arms. CONCLUSION:Compared with conventional HDCT, additional SHDCT is associated with more adverse effects and does not improve the prognosis of pts with relapsed HL. |
| Related projects: |